More on cutaneous reactions to recombinant cytokine therapy [3]

Journal of the American Academy of Dermatology

Volumn 35, Issue 4, 1996, Pages 650-

  Le Gal, F A ^a   Paul, C ^a   Chemaly, P ^a   Dubertret, L ^a   Gaspari, A A ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYTOKINE; DACARBAZINE; FOTEMUSTINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN;

CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; HUMAN; HYPOPIGMENTATION; LETTER; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; TUMOR IMMUNOLOGY; VITILIGO;

EID: 18144432824     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90707-0     Document Type: Letter

References (4)

1. JC Bystryn D Rigel RJ Friedman Prognostic significance of hypopigmentation in malignant melanoma Arch Dermatol 123 1987 1053 1055
2. KU Schallreuter C Levenig J Berger Vitiligo and cutaneous melanoma Dermatologica 183 1991 239 245
3. A Barth DL Morton The role of adjuvant therapy in melanoma management Cancer 75 1995 726 734
4. J Cui JC Bystryn Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells Arch Dermatol 131 1995 314 318